Seema Harichand-Herdt MD
Hematology/Oncology at FHMMC Comprehensive Cancer Center
Join to View Full Profile
1221 Pleasant StSte 100Des Moines, IA 50309
Phone+1 515-282-2921
Fax+1 515-282-1035
Dr. Harichand-Herdt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Seema Harichand-Herdt specializes in Oncology and is currently working as a Hematologist/Oncologist at UnityPoint Health - Iowa Methodist Medical Center in Des Moines, IA. She completed her medical education at the University of Miami Leonard M. Miller School of Medicine in 2002, and pursued her fellowship and residency at Emory University School of Medicine. Her expertise lies in conditions like amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma. She's authored several publications on various subjects within her field. Among her achievements, she received the CMS Meaningful Use Stage 1 Certification from NextGen Ambulatory EHR, NextGen Healthcare in 2013.
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009- Emory University School of MedicineResidency, Internal Medicine, 2002 - 2005
University of Miami Leonard M. Miller School of MedicineClass of 2002
Certifications & Licensure
IA State Medical License 2017 - 2027
FL State Medical License 2010 - 2019
GA State Medical License 2004 - 2019
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
Publications & Presentations
PubMed
- 134 citationsHuman Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists GuidelineCarole Fakhry, Christina Lacchetti, Lisa M. Rooper, Richard C.K. Jordan, Danny Rischin
Journal of Clinical Oncology. 2018-09-06 - 3 citationsFinal results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancersAmelia Zelnak, Toncred M. Styblo, Monica Rizzo, Sheryl G. A. Gabram, William C. Wood
Clinical Breast Cancer. 2013-06-01 - 2 citationsIdentifying subsets of metastatic breast cancer patients likely to benefit from treatment with the epothilone B analog ixabepilone.Seema Harichand-Herdt, Ruth O'Regan
American Journal of Clinical Oncology. 2010-12-01
Professional Memberships
- Member
Other Languages
- Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
